• Consensus Rating: Moderate Buy
  • Consensus Price Target: $258.00
  • Forecasted Upside: 6.37%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$242.54
▼ -0.98 (-0.40%)

This chart shows the closing price for PEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Penumbra Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEN

Analyst Price Target is $258.00
▲ +6.37% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $258.00, with a high forecast of $323.00 and a low forecast of $210.00. The average price target represents a 6.37% upside from the last price of $242.54.

This chart shows the closing price for PEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 contributing investment analysts is to moderate buy stock in Penumbra. This rating has held steady since March 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/23/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/21/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/20/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Truist FinancialBoost TargetBuy ➝ Buy$240.00 ➝ $285.00
12/17/2024OppenheimerInitiated CoverageOutperform$275.00
12/11/2024CitigroupBoost TargetNeutral ➝ Neutral$220.00 ➝ $245.00
12/11/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$190.00 ➝ $275.00
12/9/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$260.00 ➝ $323.00
11/26/2024BTIG ResearchBoost TargetBuy ➝ Buy$232.00 ➝ $270.00
11/20/2024Piper SandlerBoost TargetOverweight ➝ Overweight$235.00 ➝ $250.00
10/31/2024Piper SandlerBoost TargetOverweight ➝ Overweight$225.00 ➝ $235.00
10/31/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$244.00 ➝ $248.00
10/31/2024Needham & Company LLCReiterated RatingHold
10/25/2024Needham & Company LLCReiterated RatingHold
10/18/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$200.00 ➝ $225.00
10/16/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$176.00 ➝ $235.00
10/14/2024BTIG ResearchBoost TargetBuy ➝ Buy$224.00 ➝ $234.00
10/14/2024Truist FinancialBoost TargetBuy ➝ Buy$200.00 ➝ $235.00
10/8/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$205.00 ➝ $222.00
9/17/2024Stifel NicolausInitiated CoverageBuy$238.00
9/3/2024Leerink PartnrsUpgradeStrong-Buy
9/3/2024Leerink PartnersInitiated CoverageOutperform$263.00
8/28/2024BTIG ResearchBoost TargetBuy ➝ Buy$187.00 ➝ $224.00
8/22/2024CitigroupBoost TargetNeutral ➝ Neutral$178.00 ➝ $200.00
7/31/2024BTIG ResearchLower TargetBuy ➝ Buy$232.00 ➝ $187.00
7/31/2024Robert W. BairdLower TargetOutperform ➝ Outperform$231.00 ➝ $180.00
7/31/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$289.00 ➝ $205.00
7/31/2024Truist FinancialReiterated RatingBuy ➝ Buy$230.00 ➝ $200.00
7/31/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$272.00 ➝ $176.00
7/31/2024Needham & Company LLCReiterated RatingHold
7/31/2024Piper SandlerLower TargetOverweight ➝ Overweight$260.00 ➝ $200.00
7/31/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$289.00 ➝ $150.00
7/31/2024CitigroupDowngradeBuy ➝ Neutral$165.00 ➝ $178.00
7/16/2024Truist FinancialLower TargetBuy ➝ Buy$280.00 ➝ $230.00
7/15/2024BTIG ResearchLower TargetBuy ➝ Buy$265.00 ➝ $232.00
7/15/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$235.00 ➝ $210.00
7/10/2024CitigroupLower TargetBuy ➝ Buy$300.00 ➝ $265.00
5/8/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$284.00 ➝ $272.00
5/8/2024Piper SandlerLower TargetOverweight ➝ Overweight$290.00 ➝ $260.00
5/8/2024Needham & Company LLCReiterated RatingHold
4/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$290.00
3/22/2024Truist FinancialLower TargetBuy ➝ Buy$290.00 ➝ $280.00
2/23/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$310.00 ➝ $290.00
2/23/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$289.00
2/23/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$284.00
2/23/2024Truist FinancialLower TargetBuy ➝ Buy$300.00 ➝ $290.00
2/23/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$284.00 ➝ $250.00
1/11/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$248.00 ➝ $280.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$265.00 ➝ $295.00
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$240.00 ➝ $284.00
12/12/2023Truist FinancialBoost TargetBuy ➝ Buy$240.00 ➝ $265.00
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$335.00 ➝ $250.00
11/3/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$265.00 ➝ $240.00
10/2/2023CitigroupLower TargetBuy ➝ Buy$390.00 ➝ $320.00
9/19/2023Piper SandlerReiterated RatingOverweight ➝ Overweight$335.00
9/6/2023Morgan StanleyInitiated CoverageEqual Weight$265.00
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$349.00
8/2/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$351.00 ➝ $322.00
8/2/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$320.00 ➝ $337.00
8/2/2023Truist FinancialLower TargetBuy ➝ Buy$370.00 ➝ $345.00
8/2/2023BTIG ResearchLower Target$351.00 ➝ $308.00
7/19/2023Truist FinancialBoost Target$350.00 ➝ $370.00
7/18/2023Robert W. BairdInitiated CoverageOutperform$375.00
7/17/2023BTIG ResearchBoost Target$328.00 ➝ $351.00
7/12/2023Royal Bank of CanadaBoost Target$303.00 ➝ $349.00
7/10/2023CitigroupBoost Target$325.00 ➝ $390.00
6/26/2023Deutsche Bank AktiengesellschaftBoost Target$325.00 ➝ $376.00
6/5/2023BTIG ResearchBoost Target$312.00 ➝ $328.00
5/24/2023Piper SandlerBoost Target$300.00 ➝ $335.00
5/18/2023Truist FinancialBoost Target$320.00 ➝ $350.00
5/3/202358.comReiterated RatingMaintains
5/3/2023Deutsche Bank AktiengesellschaftBoost Target$297.00 ➝ $325.00
5/3/2023Wells Fargo & CompanyBoost Target$291.00 ➝ $320.00
5/3/2023Royal Bank of CanadaBoost Target$289.00 ➝ $303.00
5/3/2023BTIG ResearchBoost Target$301.00 ➝ $312.00
5/3/2023Piper SandlerBoost Target$285.00 ➝ $300.00
4/17/2023BTIG ResearchBoost Target$279.00 ➝ $301.00
4/3/2023CitigroupBoost TargetBuy$303.00 ➝ $325.00
3/29/2023Needham & Company LLCDowngradeBuy ➝ Hold
2/27/2023CitigroupBoost TargetBuy$270.00 ➝ $303.00
2/24/2023Canaccord Genuity GroupBoost TargetBuy$246.00 ➝ $286.00
2/24/2023Needham & Company LLCBoost TargetBuy$235.00 ➝ $300.00
2/7/2023Deutsche Bank AktiengesellschaftBoost TargetBuy$250.00 ➝ $297.00
2/1/2023JPMorgan Chase & Co.Boost TargetOverweight$254.00 ➝ $285.00
1/31/2023Truist FinancialBoost Target$255.00 ➝ $284.00
1/30/2023BTIG ResearchBoost TargetBuy$240.00 ➝ $270.00
1/30/2023Piper SandlerInitiated CoverageOverweight$275.00
1/3/2023Deutsche Bank AktiengesellschaftBoost Target$202.00 ➝ $250.00
12/20/2022Truist FinancialBoost TargetBuy$228.00 ➝ $255.00
12/12/2022Wells Fargo & CompanyBoost TargetOverweight$225.00 ➝ $255.00
12/12/2022CitigroupBoost TargetBuy$212.00 ➝ $270.00
12/5/2022BTIG ResearchBoost TargetBuy$204.00 ➝ $240.00
11/14/2022Royal Bank of CanadaBoost Target$195.00 ➝ $215.00
11/14/2022Truist FinancialBoost Target$200.00 ➝ $228.00
11/4/2022Wells Fargo & CompanyLower TargetOverweight$260.00 ➝ $225.00
11/4/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$203.00 ➝ $185.00
11/4/2022BTIG ResearchLower Target$239.00 ➝ $204.00
11/4/2022Needham & Company LLCLower TargetBuy$244.00 ➝ $235.00
11/4/2022CitigroupUpgradeNeutral ➝ Buy$217.00 ➝ $212.00
10/26/2022Deutsche Bank AktiengesellschaftBoost Target$163.00 ➝ $202.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$230.00
10/5/2022CitigroupDowngradeBuy ➝ Neutral$170.00 ➝ $217.00
9/16/2022BTIG ResearchReiterated RatingBuy$213.00 ➝ $239.00
9/13/2022Truist FinancialBoost TargetBuy$180.00 ➝ $230.00
9/9/2022Needham & Company LLCUpgradeHold ➝ Buy$244.00
8/5/2022Canaccord Genuity GroupLower TargetBuy$244.00 ➝ $189.00
7/22/2022Truist FinancialLower Target$180.00
7/21/2022Deutsche Bank AktiengesellschaftLower Target$250.00 ➝ $163.00
7/18/2022BTIG ResearchLower TargetBuy$272.00 ➝ $213.00
7/18/2022Royal Bank of CanadaInitiated CoverageOutperform$195.00
5/17/2022CitigroupLower Target$280.00 ➝ $220.00
5/4/2022Wells Fargo & CompanyLower Target$321.00 ➝ $265.00
5/3/2022William BlairReiterated RatingOutperform
4/19/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$250.00
3/18/2022BTIG ResearchInitiated CoverageBuy$272.00
3/8/2022Needham & Company LLCInitiated CoverageHold
2/23/2022Truist FinancialLower Target$350.00 ➝ $300.00
2/23/2022Canaccord Genuity GroupLower Target$335.00 ➝ $244.00
2/23/2022JPMorgan Chase & Co.Lower TargetOverweight$325.00 ➝ $300.00
2/23/2022CitigroupLower TargetBuy$300.00 ➝ $280.00
2/8/2022BTIG ResearchReiterated RatingBuy$272.00
9/16/2021Truist FinancialInitiated CoverageBuy$350.00
9/15/2021Truist FinancialInitiated CoverageBuy$350.00
8/10/2021CitigroupBoost TargetBuy$335.00 ➝ $340.00
8/10/2021BTIG ResearchBoost TargetBuy$299.00 ➝ $308.00
6/8/2021Wells Fargo & CompanyReiterated RatingBuy
6/4/2021BTIG ResearchUpgradeNeutral ➝ Buy$291.00
5/5/2021CitigroupBoost Target$325.00 ➝ $335.00
5/5/2021Wells Fargo & CompanyBoost TargetOverweight$310.00 ➝ $321.00
2/24/2021CitigroupBoost TargetBuy$255.00 ➝ $325.00
2/24/2021Wells Fargo & CompanyBoost TargetOverweight$260.00 ➝ $310.00
12/16/2020Wells Fargo & CompanyLower TargetOverweight$265.00 ➝ $215.00
12/16/2020BTIG ResearchDowngradeBuy ➝ Neutral
10/29/2020Smith Barney CitigroupBoost Target$264.00 ➝ $270.00
10/29/2020Wells Fargo & CompanyBoost TargetOverweight$255.00 ➝ $265.00
10/29/2020BTIG ResearchBoost TargetBuy$233.00 ➝ $259.00
9/29/2020BTIG ResearchInitiated CoverageBuy$233.00
9/8/2020Bank of AmericaDowngradeBuy ➝ Neutral
8/4/2020Wells Fargo & CompanyBoost TargetOverweight$205.00 ➝ $255.00
8/4/2020CitigroupBoost TargetBuy$214.00 ➝ $264.00
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$175.00 ➝ $200.00
5/8/2020CitigroupBoost TargetBuy$192.00 ➝ $214.00
3/30/2020Wells Fargo & CompanyLower TargetOverweight$195.00 ➝ $180.00
3/27/2020CitigroupLower TargetBuy$200.00 ➝ $192.00
3/4/2020CitigroupInitiated CoverageBuy$200.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/25/2024
  • 13 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/24/2024
  • 11 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/24/2024
  • 17 very positive mentions
  • 34 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
8/23/2024
  • 26 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2024
  • 19 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/22/2024
  • 18 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/21/2024
  • 39 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/21/2024

Current Sentiment

  • 39 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Penumbra logo
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $242.54
Low: $241.24
High: $245.89

50 Day Range

MA: $232.15
Low: $202.26
High: $253.59

52 Week Range

Now: $242.54
Low: $148.00
High: $277.34

Volume

943,962 shs

Average Volume

378,241 shs

Market Capitalization

$9.31 billion

P/E Ratio

282.02

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Penumbra?

The following Wall Street research analysts have issued research reports on Penumbra in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, TheStreet, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for PEN.

What is the current price target for Penumbra?

0 Wall Street analysts have set twelve-month price targets for Penumbra in the last year. Their average twelve-month price target is $258.00, suggesting a possible upside of 6.4%. Canaccord Genuity Group Inc. has the highest price target set, predicting PEN will reach $323.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $210.00 for Penumbra in the next year.
View the latest price targets for PEN.

What is the current consensus analyst rating for Penumbra?

Penumbra currently has 4 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PEN.

What other companies compete with Penumbra?

How do I contact Penumbra's investor relations team?

Penumbra's physical mailing address is One Penumbra Place, Alameda CA, 94502. The company's listed phone number is (510) 748-3200 and its investor relations email address is [email protected]. The official website for Penumbra is www.penumbrainc.com. Learn More about contacing Penumbra investor relations.